WO2025062425 - AN ORAL SOLID PHARMACEUTICAL FORMULATION OF ENZALUTAMIDE
National phase entry:
Publication Number
WO/2025/062425
Publication Date
27.03.2025
International Application No.
PCT/IN2024/051781
International Filing Date
18.09.2024
Title **
[English]
AN ORAL SOLID PHARMACEUTICAL FORMULATION OF ENZALUTAMIDE
[French]
FORMULATION PHARMACEUTIQUE SOLIDE ORALE D'ENZALUTAMIDE
Applicants **
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED
Inventors
SHAH, Dharmesh Mahendrabhai
BADIGER, Aravind Manappa
UPADHYE, Abhijeet Ashokrao
PANCHAL, Samir Babulal
Priority Data
202321062597
18.09.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1948 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 2024 | |
| South Korea | Filing, Examination, Granting | 1765 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,053
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to novel oral solid pharmaceutical formulation of enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. An enzalutamide pharmaceutical formulation comprising a one or more pharmaceutically acceptable polymers is provided by the present invention. In addition, the present invention also provides an improved process for preparation of enzalutamide oral solid pharmaceutical formulation.[French]
La présente invention concerne une nouvelle formulation pharmaceutique solide orale d'enzalutamide ou d'un sel pharmaceutiquement acceptable de celui-ci et un ou plusieurs excipients pharmaceutiquement acceptables. La présente invention concerne une formulation pharmaceutique d'enzalutamide comprenant un ou plusieurs polymères pharmaceutiquement acceptables. De plus, la présente invention concerne également un procédé amélioré de préparation d'une formulation pharmaceutique solide orale d'enzalutamide.